【紹介文献】
Polygenic architecture informs potential vulnerability to drug-induced liver injury
Koido et al., Nat Med. 2020 Oct;26(10):1541-1548.
doi: 10.1038/s41591-020-1023-0
【発表概要】
薬剤性肝障害（DILI）は、医薬品開発プログラムの終了や医薬品の市場撤去の主な原因となっています。DILIの多遺伝子リスクスコア（PRS）を開発し、PRSによりfasiglifam、amoxicillin-clavulanate、flucloxacillinを投与した患者から得た初代肝細胞およびiPS由来肝オルガノイドを用いて、DILIの感受性を予測した研究について紹介します。
【Summary】
Drug-induced liver injury (DILI) is a major cause of termination of drug development programs and withdrawal of drugs from the market. In this report, they developed a polygenic risk score (PRS) for DILI and used the PRS to predict susceptibility to DILI in patients treated with fasiglifam, amoxicillin-clavulanate, and flucloxacillin, and primary liver cells and iPS-derived hepatic organoids from patients treated with amoxicillin-clavulanate, flucloxacillin.
(2023.5.18 Shonan iPark Science Cafe 146th)
